Anupam Rasayan India Limited (ANURAS)
Submission of Press Release titled Anupam Rasayan concludes acquisition of Bliss GVS Pharma, makes third strategic step towards building an Integrated Global Pharma Platform.
Anupam Rasayan completed acquisition of 48.2% controlling stake in Bliss GVS Pharma at ₹299/share.
- Acquisition expands presence into finished dosage formulations.
- Funded by ₹300 Cr term loan and ₹1,450 Cr from financial investors led by Bain Capital.
- Bliss GVS Pharma operates 6 manufacturing sites with ~30% capacity utilization.
- Combined platform pro-forma revenue exceeds ₹4,000 Cr with EBITDA ~₹834 Cr.
- Acquisition marks forward integration complementing specialty chemicals and intermediates.
- Transaction at ~24x LTM earnings, earnings-accretive for Anupam Rasayan.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ANURAS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ANURAS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Anupam Rasayan India Limited
Important.
The summary above is generated automatically from Anupam Rasayan India Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.